| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4293637
Max Phase: Preclinical
Molecular Formula: C22H30Cl2N6O2
Molecular Weight: 408.51
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CN(C(=O)CCCCC(=O)N(C)c1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1.Cl.Cl
Standard InChI: InChI=1S/C22H28N6O2.2ClH/c1-27(17-11-7-15(8-12-17)21(23)24)19(29)5-3-4-6-20(30)28(2)18-13-9-16(10-14-18)22(25)26;;/h7-14H,3-6H2,1-2H3,(H3,23,24)(H3,25,26);2*1H
Standard InChI Key: UBVWBIIRSDRMTF-UHFFFAOYSA-N
Associated Targets(Human)
A549 127892 Activities
Associated Targets(non-human)
Pneumocystis carinii 749 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Luciferin 4-monooxygenase 66902 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 408.51 | Molecular Weight (Monoisotopic): 408.2274 | AlogP: 2.44 | #Rotatable Bonds: 9 |
| Polar Surface Area: 140.36 | Molecular Species: BASE | HBA: 4 | HBD: 4 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: | CX Basic pKa: 11.79 | CX LogP: 0.93 | CX LogD: -3.88 |
| Aromatic Rings: 2 | Heavy Atoms: 30 | QED Weighted: 0.29 | Np Likeness Score: -0.52 |
References
| 1. Maciejewska D, Żabiński J, Rezler M, Kaźmierczak P, Collins MS, Ficker L, Cushion MT.. (2017) Development of highly active anti-Pneumocystis bisbenzamidines: insight into the influence of selected substituents on the in vitro activity., 8 (10): [PMID:30108719] [10.1039/C7MD00445A] |
Source
Source(1):